Spotlight on Lenalidomide in Relapsed or Refractory Multiple Myeloma
In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥18 years) who have received at least one prior antimyeloma therapy. The key therapeutic mechanisms of action of lenalidomide (a thalidomide analog) reside in its immunomodulatory, antiproliferative, and anti-angiogenic properties. In patients with multiple myeloma, lenalidomide has dual effects, exerting a direct antitumor response by inhibiting proliferation and by inducing apoptosis of tumor cells. Lenalidomide also acts to enhance the immune system by inducing the activation of immune effector cells, such as T cells and natural killer cells, and inducing cytokine production.
In the pivotal MM-009 and MM-010 phase III registration trials, treatment with lenalidomide plus dexamethasone was effective and had a manageable safety and tolerability profile in relapsed or refractory patients with multiple myeloma. In robust pharmacoeconomic analyses based on these trials, relative to dexamethasone, lenalidomide plus dexamethasone treatment met the assumed willingness-to-pay threshold for cost effectiveness from the UK and Scottish healthcare payer perspective in this patient population. The UK National Institute for Health and Clinical Excellence and the Scottish Medicines Consortium considered that the health economic case for lenalidomide plus dexamethasone treatment was demonstrated for patients who had received at least two prior antimyeloma therapies. In addition, in pharmacoeconomic analyses based on indirect comparisons of clinical efficacy, regulatory agencies in Norway and Sweden considered that lenalidomide plus dexamethasone treatment was cost effective relative to bortezomib in patients who have received at least one prior antimyeloma therapy. Furthermore, compared with placebo plus dexamethasone, treatment with lenalidomide plus dexamethasone significantly prolonged the median time to progression, increased overall response rates and prolonged overall survival, with significantly longer median time to progression and overall response rates observed for all subgroups of patients. Thus, combination therapy with lenalidomide plus dexamethasone provides a valuable option for the treatment of relapsed or refractory adult patients with multiple myeloma.
- 13.European Medicines Agency. Summary of product characteristics: Revlimid® [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/doument_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf [Accessed 2010 Sep 13]
- 14.Celgene Corporation. Revlimid® (lenalidomide) 5mg, 10mg, 15mg and 25 mg capsules: US prescribing information [online]. Available from URL: http://www.revlimid.com/pdf/REVLIMID_PI.pdf [Accessed 2010 Aug 9]
- 25.Ishak J, Dimopoulos MA, Weber D, et al. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone [abstract no. 3708]. Blood 2008; 112 (11)Google Scholar
- 26.Delforge M, Blau IW, Hernandez MT, et al. Post-Approval Safety Study (PASS) of lenalidomide compared with other treatments in patients with relapsed or refractory multiple myeloma: evaluation of peripheral neuropathy in the first 1011 patients [abstract no. 1939]. Blood 2010; 116 (21)Google Scholar
- 27.Deniz B, Morgan G, Schey S, et al. Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK [abstract no. 2400]. Blood 2008; 112 (11)Google Scholar
- 28.Deniz HB, Ishak KJ, Edwards DR, et al. Economic evaluation of lenalidomide for the treatment of multiple myeloma in Wales in patients who have received at least one prior therapy [abstract no. 0804]. Haematologica 2008; 93Suppl. 1: 320–1Google Scholar
- 30.National Institute for Health and Clinical Excellence. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy: NICE technology appraisal guidance 171 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA171GuidanceWord.doc [Accessed 2010 Sep 30]
- 31.Scottish Medicines Consortium. Resubmission: lenalidomide 5mg, 10mg, 15mg and 25 mg capsules (Revlimid®): no. (441/08) [online]. Available from URL: http://www.scottishmedicines.org.uk/files/lenalidomide_Revlimid_FINAL_April_2010_Resubmission_Amended_160610.pdf [Accessed 2011 Mar1]
- 32.Statens legemiddelverk. Reimbursement report lenalidomide (Revlimid) to treatment of multiple myeloma: assessment of the application for preapproved reimbursement [online]. Available from URL: http://www.legemiddelverket.no/upload/Refusjonsrapport_Revlimid.pdf [Accessed 2011 Mar 8]
- 33.Tandvårdsoch Läkemedelsförmånsverket. Dental and Pharmaceutical Benefits Agency, TLV decides that the following drugs should be included in the reimbursement from 2010-06-30 to the table specified prices. TLV determines the alternative price to the same amount of AIP [online]. Available from URL: http://www.tlv.se/Upload/Beslut_2010/bes100701-revlimid.pdf [Accessed 2011 Mar 2]